Literature DB >> 16418492

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.

Alexander Kröber1, Johannes Bloehdorn, Sebastian Hafner, Andreas Bühler, Till Seiler, Dirk Kienle, Dirk Winkler, Markus Bangerter, Richard F Schlenk, Axel Benner, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer.   

Abstract

PURPOSE: Immunoglobulin heavy chain variable-region (VH) gene mutation status and zeta-associated protein 70 (ZAP-70) expression are correlated in chronic lymphocytic leukemia (CLL), but their concordance is variable. The goal of this study was to elucidate additional factors potentially characterizing their discordance. PATIENTS AND METHODS: We evaluated ZAP-70 expression by flow cytometry, VH status by DNA sequencing, and genomic aberrations by fluorescence in situ hybridization in 148 CLL patients. The parameters were analyzed for their associations and their individual prognostic impact.
RESULTS: ZAP-70 expression and VH mutation status were strongly associated in CLL without additional genetic high-risk-features as defined by the absence of 11q or 17p deletion and V3-21 usage (concordance 84%). In contrast, the proportion of discordant cases was significantly higher (39%), if such additional genetic high-risk features were present. Discordant cases with V3-21 usage were almost exclusively ZAP-70 positive and VH mutated (89%), whereas all but one of the discordant cases with high-risk aberrations were ZAP-70 negative and VH unmutated (92%). By multivariate regression analysis, two models were developed, which both include high-risk genomic aberrations and, alternatively, VH mutation status and V3-21 usage or ZAP-70 expression as independent outcome predictors.
CONCLUSION: There were characteristic modes of discordance between ZAP-70 and VH mutation status depending on the presence or absence of additional genetic high-risk features such as 11q and 17p deletion or V3-21 usage. Although the biologic background for these findings is yet to be determined, these data have biologic and clinical implications regarding ZAP-70 as a pathogenic factor and outcome predictor, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418492     DOI: 10.1200/JCO.2005.03.7184

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

1.  Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.

Authors:  Rachel Sargent; Dan Jones; Lynne V Abruzzo; Hui Yao; Jaime Bonderover; Marissa Cisneros; William G Wierda; Michael J Keating; Rajyalakshmi Luthra
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

2.  Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia.

Authors:  Shelly R Gunn; Mansoor S Mohammed; Mercedes E Gorre; Philip D Cotter; Jaeweon Kim; David W Bahler; Sergey N Preobrazhensky; Russell A Higgins; Aswani R Bolla; Sahar H Ismail; Daphne de Jong; Eric Eldering; Marinus H J van Oers; Clemens H M Mellink; Michael J Keating; Ellen J Schlette; Lynne V Abruzzo; Ryan S Robetorye
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

3.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

4.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

Review 5.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

Review 6.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 7.  Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.

Authors:  Spencer H Bachow; Nicole Lamanna
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

8.  Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Authors:  Francesca M Rossi; Maria Ilaria Del Principe; Davide Rossi; Maria Irno Consalvo; Fabrizio Luciano; Antonella Zucchetto; Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Marco Fangazio; Dania Benedetti; Massimo Degan; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2010-03-08       Impact factor: 5.531

9.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Authors:  Joan H Admirand; Ronald J Knoblock; Kevin R Coombes; Constantine Tam; Ellen J Schlette; William G Wierda; Alessandra Ferrajoli; Susan O'Brien; Michael J Keating; Rajyalakshmi Luthra; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.